28 June 2024 - First of multiple planned global submissions for lifileucel in 2024 and 2025.
Iovance Biotherapeutics submitted a marketing authorisation application to the EMA for lifileucel, a TIL cell therapy, for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.